On Tuesday, Alnylam Pharmaceuticals (NASDAQ:ALNY) saw its price target increased by TD (TSX:TD) Cowen from $260.00 to $282.00, while the firm maintained a Buy rating on the stock. The revision follows the release of what the analyst described as "best case scenario" data from the HELIOS-B study. This positive data is seen as a strong indicator for potential approval of Alnylam's treatment in the United States, European Union, and Japan.
The analyst's optimism stems from the study's statistically significant results on all primary and secondary endpoints in both the intention-to-treat and monotherapy populations. Based on these outcomes, the analyst anticipates a straightforward approval process. The firm has projected that Alnylam could achieve $5.1 billion in peak global sales, assuming a gross price of $225,000 at launch and capturing 24% of the market at its peak.
The HELIOS-B study's favorable results are particularly noteworthy as they could pave the way for Alnylam's treatment to become a significant player in its market segment. The analyst's increased price target reflects confidence in the drug's market potential and the likelihood of its approval based on the recent data.
Alnylam Pharmaceuticals, which is part of the biopharmaceutical industry, focuses on developing therapies for genetically defined diseases. The HELIOS-B study is a critical part of the company's efforts to expand its product portfolio and deliver new treatments to patients in need.
Investors and market watchers will likely keep a close eye on Alnylam's progress towards regulatory approval and the subsequent commercial launch of the treatment studied in the HELIOS-B trial. The company's stock performance may be influenced by these developments as they unfold.
In other recent news, Alnylam Pharmaceuticals reported successful Phase 3 trial results for its therapeutic, vutrisiran, designed for patients with TTR amyloidosis with cardiomyopathy (ATTR-CM).
The trial, named HELIOS-B, showcased significant improvements in cardiovascular outcomes, including survival rates. This success has led to several analyst firms maintaining positive ratings, including a Buy rating from H.C. Wainwright with a $400 target, and an Equalweight rating from Morgan Stanley (NYSE:MS), which raised its price target to $250 from $164.
Alnylam's Q1 2024 revenues reached $365 million, marking a 32% increase from the same period the previous year, fueled by its Transthyretin (TTR) franchise. The company is targeting net product revenues between $1.4 billion and $1.5 billion for 2024.
Alnylam plans to submit a supplemental New Drug Application to the FDA for vutrisiran in ATTR-CM by the end of 2024. This sets the stage for a potential market launch of vutrisiran for ATTR-CM treatment in the second half of 2025.
Still, TD Cowen maintained a Buy rating on shares of BridgeBio Pharma (NASDAQ:BBIO), suggesting that Alnylam's results fall short of the high bar set by BridgeBio's ATTRibute-CM trial. The full study results presentation at the ESC conference will be crucial for evaluating the comparative effectiveness of the treatments studied.
These are recent developments and should be considered in the context of the company's overall performance.
InvestingPro Insights
Alnylam Pharmaceuticals' recent positive momentum is echoed in the real-time data provided by InvestingPro. With a significant 44.87% return over the last week and a 50.85% return over the last month, the company is trading near its 52-week high. This upward trajectory is further supported by a robust 75.2% revenue growth in the last twelve months as of Q1 2024, showcasing a strong financial performance.
Still, it is important to note that analysts do not anticipate Alnylam will be profitable this year, and the company has not been profitable over the last twelve months. The InvestingPro Tips highlight that while the stock may be in overbought territory according to the RSI, the company's liquid assets exceed its short-term obligations, suggesting a solid financial position in the near term.
For investors looking to delve deeper into Alnylam's financials and stock performance, there are additional InvestingPro Tips available on InvestingPro. Utilize coupon code PRONEWS24 for an extra 10% off a yearly or biyearly Pro and Pro+ subscription to access these insights, which could provide valuable context as Alnylam progresses towards the potential approval and commercial launch of its new treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.